At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 74 enrolled
Drug / intervention
zonisamide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Zonisamide Augmentation of Varenicline Treatment for Smoking Cessation
In Brief
A Phase 2 clinical trial evaluating zonisamide and placebo for Nicotine Dependence. Completed, enrolled 74 participants across 1 site.
Detailed Summary
Randomized trial to evaluate whether zonisamide can enhance varenicline-induced smoking cessation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNicotine Dependence
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA)
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2012
First PostedSep 2012
Primary CompletionMay 2014
TodayJul 2026
First PostedSep 17, 2012
Enrollment StartSep 1, 2012
Primary CompletionMay 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 13.8 years ago
Interventions
zonisamidedrug
In addition to zonisamide vs placebo treatment, varenicline tablets will be dispensed with specific instructions to take at the recommended doses for smoking cessation Participants will receive brief smoking cessation counseling and referral to a quitline
placebodrug